⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596196 | 0.92 | — | — | |
| SCHEMBL121308 | 0.80 | — | — | |
| SCHEMBL141622 | 0.64 | CRBN (0.53) | — | |
| SCHEMBL1335950 | 0.64 | — | — | |
| SCHEMBL23028960 | 0.61 | CRBN (0.80) | — | |
| SCHEMBL6049487 | 0.61 | CRBN (0.80) | — | |
| SCHEMBL5909153 | 0.61 | CRBN (0.80) | — | |
| SCHEMBL7888543 | 0.61 | CRBN (0.80) | — | |
| SCHEMBL1395582 | 0.61 | CRBN (0.50) | — | |
| SCHEMBL8801853 | 0.61 | CRBN (0.80) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | claimed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | claimed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | claimed |
| EP-1973408-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | claimed |
| WO-2007081690-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| WO-2007081690-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |